Report Summarizes Cancer Study Findings from U.S. Food and Drug Administration (FDA) (Us Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, ...)

Press/Media: Press / Media

PeriodJun 25 2024